Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 12/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978741 | 0.90 | CHEK2 (0.39) | CHEK2HPSESIRT2 | |
| SCHEMBL4295298 | 0.90 | CHEK2 (0.45) | CHEK2HPSEDHODH | |
| SCHEMBL4295203 | 0.84 | THRB (0.34) | — | |
| SCHEMBL3977650 | 0.83 | CHEK2 (0.44) | CHEK2 | |
| SCHEMBL3981701 | 0.82 | THRA (0.39) | — | |
| SCHEMBL3981706 | 0.82 | THRA (0.39) | — | |
| SCHEMBL3985944 | 0.82 | THRA (0.39) | — | |
| SCHEMBL4297760 | 0.82 | THRB (0.37) | — | |
| SCHEMBL4304033 | 0.81 | THRB (0.34) | CHEK2 | |
| SCHEMBL4304109 | 0.81 | THRB (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | claimed |
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-7531149-B2 | Heating a mixture of a metal fatty acid salt, a fatty acid, and a hydrocarbon solvent to at least 300 degrees C.; monodisperse size distribution; Fe3O4, Cr2O3, MnO, Co3O4, NiO, ZnO, SnO2, and In2O3; stearic, oleic or myristic acid; octadecene, n-eicosane, n-tetracosane solvents | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2009-05-12 | — | — | US | disclosed |
| US-20060211152-A1 | Synthetic control of metal oxide nanocrystal sizes and shapes | NATIONAL SCIENCE FOUNDATION | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318514-A1 | Novel Pharmaceutical Compositions | TSHR, TRHR, THRA | CHEK2 3149/4885HPSE 3148/4885EGFR 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.